These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16847417)

  • 1. A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2.
    Pao D; Smit E; Imami N; Fisher M
    AIDS; 2006 Jul; 20(11):1564-5. PubMed ID: 16847417
    [No Abstract]   [Full Text] [Related]  

  • 2. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.
    Masquelier B; Capdepont S; Neau D; Peuchant O; Taupin JL; Coakley E; Lie Y; Carpentier W; Dabis F; Fleury HJ;
    AIDS; 2007 Jan; 21(1):103-6. PubMed ID: 17148975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severely immunocompromised HIV-infected paediatric patient with drug-resistant cytomegalovirus infection treated with subcutaneous interleukin-2.
    Soler-Palacín P; Clemente S; Martín A; Cabañas MJ; Hidalgo E; Figueras C
    J Paediatr Child Health; 2009 Apr; 45(4):234-5. PubMed ID: 19426382
    [No Abstract]   [Full Text] [Related]  

  • 5. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
    Delaugerre C; Marcelin AG; Soulié C; Chaix ML; Katlama C; Girard PM; Calvez V; Morand-Joubert L
    AIDS; 2007 Jun; 21(10):1365-7. PubMed ID: 17545716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Highly active antiretroviral therapy].
    Jablonowski H
    MMW Fortschr Med; 2009 Apr; 151(18):58-61. PubMed ID: 19769079
    [No Abstract]   [Full Text] [Related]  

  • 11. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
    Marziali M; De Santis W; Carello R; Leti W; Esposito A; Isgrò A; Fimiani C; Sirianni MC; Mezzaroma I; Aiuti F
    AIDS; 2006 Oct; 20(16):2033-41. PubMed ID: 17053349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study.
    Poggensee G; Kücherer C; Werning J; Somogyi S; Bieniek B; Dupke S; Jessen H; Hamouda O;
    HIV Med; 2007 Nov; 8(8):511-9. PubMed ID: 17944684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.
    Hasson H; Mantelli B; Biswas P; Malnati M; Gianotti N; Vecchi A; Nozza S; Cernuschi M; Boeri E; Clerici M; Lazzarin A; Beretta A
    J Med Virol; 2007 Nov; 79(11):1640-9. PubMed ID: 17854028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
    Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
    J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.